期刊文献+

无菌体液中大肠埃希菌对头孢吡肟耐药的危险因素分析 被引量:2

Risk factors associated with cefepime-resistant Escherichia coli isolates in sterile body fluid
原文传递
导出
摘要 目的探讨无菌体液中大肠埃希菌对头孢吡肟耐药的危险因素。方法收集2012年7月至2013年8月间医院在无菌体液中分离的288株大肠埃希菌,对患者病例做回顾性病例对照分析。病例组为96株头孢吡肟耐药菌株,对照组为192株头孢吡肟敏感菌株。Logistic回归模型被用来分析大肠埃希菌对头孢吡肟耐药的独立危险因素。结果大肠埃希菌对头孢吡肟的耐药率为33.3%。产超广谱β-内酰胺酶(ESBLs)、先前使用抗生素(尤其是头孢菌素)、男性、先前住院天数≥10 d、机械通气、引流管、导尿管和静脉置管等是大肠埃希菌对头孢吡肟耐药的主要危险因素。其中,产ESBLs、先前使用抗生素、先前住院天数≥10 d和男性是其独立危险因素。结论有上述危险因素存在的患者,尤其是男性,应尽量缩短住院时间,减少侵入性操作,慎用头孢菌素类药物,以减少头孢吡肟耐药菌株的出现。 Objective To identify the risk factors for acquisition of cefepime (FEP) resistance among Escherichia coli (E. coli) isolates in sterile body fluid. Methods A total of 288 successive and non-duplicate E. coli strains isolated from sterile body fluid specimens during July 2012 to August 2013 in our department were recruited for case-control study. Ninety-six case was defined as FEP-resistant isolates while 192 cases with FEP-susceptive isolates served as control. Logistic regression was performed to evaluate the independent risk factors. Results Out of the 288 total isolates, 33.3% (96/288) were resistant to FEP. Production of extended spectrum beta-lactamases (ESBLs), previous antibiotic use, ≥ 10 d of hospital stay before infection and male were the independent risk factors associated with FEP-resistant E. coli isolates. Other major risk factors included previous use of cephalosporins, mechanical ventilation, drainage tube, urinary or intravenous catheterization. Conclusion Patients ( especially male) with above-mentioned risk factors should be kept to a shorter hospital stay, less invasive operations and more cautious use of cephalosporins in order to control the emergence of cefepime-resistant strains.
出处 《第三军医大学学报》 CAS CSCD 北大核心 2014年第19期2030-2033,共4页 Journal of Third Military Medical University
基金 国家临床重点专科建设项目[2010(305)]~~
关键词 头孢吡肟 大肠埃希菌 耐药 危险因素 无菌体液 cefepime Escherichia coli resistance risk factors sterile body fluid
  • 相关文献

参考文献19

  • 1Shi Q, Ding F, Sang R, et al. Drug use evaluation of cefepime in the first affiliated hospital of Bengbu medical college: a retrospective and prospective analysis[J]. BMC Infect Dis, 2013, 13: 160.
  • 2谭正芳.2006~2010年大肠埃希菌耐药性分析[J].检验医学与临床,2011,8(11):1366-1367. 被引量:7
  • 3马越,李景云,胡昌勤,金少鸿,国家细菌耐药性监测网.头孢吡肟等抗生素对革兰阴性杆菌体外敏感性连续四年耐药性监测分析[J].中华检验医学杂志,2004,27(11):747-751. 被引量:22
  • 4Marschall J, Zhang L, Foxman B, et al. Both host and pathogen factors predispose to Escherichia coli urinary-source bacteremia in hospitalized patients[J]. Clin Infect Dis, 2012, 54(12) : 1692 -1698.
  • 5朱任媛,张小江,徐英春,杨青,汪复,朱德妹,倪语星,孙景勇,孙自镛,简翠,胡云建,艾效曼,张泓,李万华,贾蓓,黄文祥,王传清,薛建昌,魏莲花,吴玲,卓超,苏丹虹,张朝霞,季萍,徐元宏,沈继录,单斌,杜艳,俞云松.2011年中国CHINET无菌体液细菌分布和耐药性监测[J].中国感染与化疗杂志,2013,13(5):349-356. 被引量:18
  • 6Paterson D L, Bonomo R A. Extended-spectrum beta-lactamases: a clinical update [ J ]. Clin Microbiol Rev, 2005, 18 (4) : 657 - 686.
  • 7Walsh T R. The emergence and implications of metallo-beta-lactamases in Gram-negative bacteria [ J ]. Clin Microbiol Infect, 2005, 11 ( Suppl 6) : 2 -9.
  • 8Sidjabat H E, Paterson D L, Adams-Haduch J M, et al. Molecular epidemiology of CTX-M-producing Escherichia coli isolates at a tertiary medical center in western Pennsylvania [ J ]. Antimicrob Agents Chemother, 2009, 53( 11 ) : 4733 -4739.
  • 9Liu W, Chela L, Li H, et al. Novel CTX-M t beta t -lactamase genotype distribution and spread into multiple species of Enterobacteriaceae in Changsha, Southern China [ J ]. J Antimicrob Chemother, 2009, 63 (5) : 895 -900.
  • 10Mansouri M, Ramazanzadeh R, Norabadi P, Cefepime resistance and associated risk factors among Escheriehia eoli strains isolated from clinical specimens[J]. Chemotherapy, 2011,57(2): 134-137.

二级参考文献31

  • 1马越,李景云,胡昌勤,金少鸿,国家细菌耐药性监测网.头孢吡肟等抗生素对革兰阴性杆菌体外敏感性连续四年耐药性监测分析[J].中华检验医学杂志,2004,27(11):747-751. 被引量:22
  • 2Perez F,Hujer AM,Hujer KM,et al.Global challenge of multidruyresistant Acinetobacter baumannii[J].Antimicrob Agents chemother,2007,51(10):3471-3484.
  • 3Duncan RA. Controlling use of antimicrobial agents. Infect Control Hosp Epidemiol, 1997, 18(4): 260-266
  • 4Mebis J, Goossens H, Bruyneel P, et al. Decreasing antibiotic resistance of Enterobacteriaceae by introducing a new antibiotic combination therapy for neutropenic fever patients. Leukemia, 1998, 12(10): 1627-1629
  • 5Landman D, Chockalingam M, Quale J. Reduction in the incidence of methicillin-resistant Staphylococcus aureus and ceftazidime-resistant Klebsiella pneumoniae following changes in a hospital antibiotic formular. Clin Infect Dis, 1999, 28(5): 1062-1066
  • 6Rahal JJ, Urban C, Horn D, Freeman K, et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA, 1998, 280(14): 1233-1237
  • 7Knaus WA, Draper EA, Wagner DP, et al. APACHE II: a severity of disease classification system. Crit Care Med, 1985, 13(10): 818-829
  • 8Vincent JL, Moreno R, Takata J,et al. The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/failure. Intens Care Med, 1996, 22(7): 707-710
  • 9Ibrahim EH, Sherman G, Ward S, et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest, 2000, 118(1): 146-155
  • 10Xu YC, Chen MJ, Biedenbach DJ, et al. Evaluation of the in vitro antimicrobial activity of cefepime compared to other broad-spectrum beta-lactams tested against recent clinical isolates from 10 Chinese hospitals. Diagn Microbiol Infect Dis, 1999, 35(2): 1

共引文献75

同被引文献18

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部